➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Medtronic
Johnson and Johnson
Colorcon
Merck

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LOTEMAX

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Lotemax

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00366691 ↗ Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation Completed Medical University of South Carolina Phase 4 2006-02-01 The purpose of this study is to compare the effectiveness of Acular LS┬« and Lotemax┬« in the prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan, Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery.
NCT00407043 ↗ Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed Bausch & Lomb Incorporated Phase 4 2006-11-01 To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.
NCT00407043 ↗ Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed Ophthalmic Consultants of Long Island Phase 4 2006-11-01 To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry eye. It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the stinging with cyclosporine administration and the dry eye signs and symptoms experienced during the initiation of therapy.
NCT00560638 ↗ Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye Completed Bausch & Lomb Incorporated Phase 2 2005-11-01 This was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.
NCT00705159 ↗ Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed Bausch & Lomb Incorporated Phase 4 2008-06-01 The objective of this study is to evaluate the safety and effectiveness of Zylet in comparison with Lotemax, Tobramycin and the vehicle of Zylet for the treatment of blepharoconjunctivitis in pediatric subjects.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lotemax

Condition Name

Condition Name for Lotemax
Intervention Trials
Inflammation 4
Dry Eye Disease 3
Pseudophakia 2
Cataract 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lotemax
Intervention Trials
Keratoconjunctivitis Sicca 7
Dry Eye Syndromes 7
Inflammation 6
Cataract 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lotemax

Trials by Country

Trials by Country for Lotemax
Location Trials
United States 18
Israel 1
Korea, Republic of 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lotemax
Location Trials
Massachusetts 5
New York 3
California 2
New Jersey 2
Florida 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lotemax

Clinical Trial Phase

Clinical Trial Phase for Lotemax
Clinical Trial Phase Trials
Phase 4 11
Phase 3 2
Phase 2 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lotemax
Clinical Trial Phase Trials
Completed 12
Unknown status 4
Not yet recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lotemax

Sponsor Name

Sponsor Name for Lotemax
Sponsor Trials
Bausch & Lomb Incorporated 11
Massachusetts Eye and Ear Infirmary 3
University of Michigan 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lotemax
Sponsor Trials
Other 14
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Dow
Express Scripts
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.